All Oncology News

Researchers at Northwestern Medicine have developed a new and faster approach to determine if a treatment for the brain cancer glioblastoma is working.

A focus on her passion for leukemia research and genuine care for her patients enabled Wendy Stock, MD, to rise above—one step at a time—as a mentor, leader, and pioneer.

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.

A LSU LCMC Health Cancer Center study provides new insights that could lead to more effective, personalized treatments in TNBC.

Richard Gorlick, MD, is a leading physician-scientist whose career and lifelong commitment to improving outcomes for children with cancer has been shaped by his personal journey as a childhood cancer survivor.

Glofitamab and epcoritamab were both associated with early disease progression in relapsed/refractory large B-cell lymphoma.

David G. Pfister, MD, developed a combined modality organ preservation treatment program that shifted the landscape of head and neck cancers.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

Primo Nery “Lucky” Lara Jr, MD, has built a genitourinary oncology career inspired by optimism, rooted in perseverance, expanded by innovative thinking, and strengthened by a belief in the power of team science.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

Brian Wolpin, MD, MPH, is driving advances in early detection, molecular diagnostics, and precision therapies for patients with gastrointestinal cancers

UC Davis Health joins an elite group recognized for top-tier pancreatic cancer care and research.

Ayalew Tefferi, MD, tirelessly advances medicine, driven by a philosophy that physical and intellectual journeys are one.

To ensure the generalizability of clinical trial results and equitable treatment access, enrollment must reflect the diversity of the patient population.

Heather McArthur, MD, MPH, FASCO, elaborates on clinical trial data for palazestrant monotherapy in breast cancers.

Rashmi Khanal, MD , of Fox Chase Cancer Center discusses how TIL therapy can give patients with aggressive disease more hope for the future.

Experts convene during an OncLive Peer Exchange to discuss the evolving treatment paradigm in HR-positive, HER2-negative breast cancer.

Obe-cel was associated with lower rates of CRS and ICANS vs brexu-cel in relapsed or refractory acute lymphoblastic leukemia.

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program received exceptional ratings from the CIBMTR.

Bezuclastinib normalized key bone marrow pathology in nonadvanced systemic mastocytosis.

Zev A. Wainberg, MD, discusses different palliative chemotherapy regimens, their use cases, and other recent developments in pancreatic cancer.

Balazs Halmos, MD, MS, and Jamie E. Chaft, MD, discuss how safety considerations contribute to treatment selection in NSCLC.

Neoadjuvant SABR before nephrectomy improved 12-month RFS vs surgery alone in patients with RCC with IVC tumor thrombus, with manageable safety.

Roswell Park Comprehensive Cancer Center welcomes Brian Higgins to its board of directors.

The FDA has granted breakthrough therapy designation to JSKN003 in HER2+ platinum-resistant ovarian cancer.

Ceralasertib plus durvalumab did not improve overall survival vs docetaxel in previously treated advanced non–small cell lung cancer.

Tsewang Tashi, MD, discusses long-term avapritinib data in indolent systemic mastocytosis from part 3 of the PIONEER trial.

In the BARCODE1 screening study, prostate cancer testing by polygenic risk score identified a higher percentage than PSA testing or MRI.

Orca-T given with reduced intensity conditioning led to robust myeloid/T-cell engraftment and low rates of acute GVHD in hematologic malignancies.

Interim phase 2 data show nab-sirolimus plus letrozole produced an ORR of 41% and 13.6-month PFS with manageable safety in endometrioid endometrial cancer.